- INTERNATIONAL JOURNAL OF ONCOLOGY 26: 241-246, 2005 In Vivo and In Vitro effect of baicalein
- Biomedical Paper Computer Model for Cryosurgery of the Prostate
- (CANCER RESEARCH 52, 5829-58.12. October 15. 1992] Advances in Brief
- INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 6: 521-526, 2000 Curcumin inhibits lipoxygenase by binding to its central
- Abstract. Plasminogen activator inhibitor (PAI-1) is an anti-cancer agent that inhibits plasmin driven proteolysis, limiting
- ONCOLOGY REPORTS 6: 523-526, 1999523 Angiostatic activity of synthetic inhibitors of urokinase type
- Abstract. Epidemiological studies have shown that the clinical incidence of prostate cancer varies by geographical area. When
- A Novel Form of the Plasminogen Activator Inhibitor Created by Cysteine Mutations Extends Its Half-Life: Relevance to
- Abstract. Plasminogen activator inhibitor-1 (PAI-1) is the major specific inhibitor of tissue-type plasminogen activator
- INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 11: 287-291, 2003 Spatial distribution of liposome encapsulated tin etiopurpurin
- Structural and Thermochemical Characterization of Lipoxygenase-Catechol Chau Pham, Jerzy Jankun, Ewa Skrzypczak-Jankun, Robert A. Flowers, II, and Max O. Funk, Jr.*,
- Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and
- The Prostate 66:779 ^787 (2006) Vascular Endothelial Growth Factor Productionin
- Abstract. Plasminogen activator inhibitor-1 (PAI-1), a member of the serpin super-family, forms a covalent complex with its
- OPTICAL CHARACTERISTICS OF THE CANINE PROSTATE AT 665 NM SENSITIZED WITH TIN ETIOPURPURIN DICHLORIDE: NEED FOR
- INSTITUTE OF PHYSICS PUBLISHING PHYSICS IN MEDICINE AND BIOLOGY Phys. Med. Biol. 49 (2004) 32093225 PII: S0031-9155(04)76358-7
- Acta Cryst. (2004). D60, 613615 DOI: 10.1107/S0907444904000861 613 short communications
- SHORT COMMUNICATION Lipoxygenase Interactions With Natural Flavonoid,
- INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 12: 415-422, 2003 Inhibition of lipoxygenase by (-)-epigallocatechin gallate
- ONCOLOGY REPORTS 8: 463-470, 2001 Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer
- ONCOLOGY REPORTS 7: 879-882, 2000 Expression of soluble urokinase plasminogen activator
- Vol. 4, 869-877, April 1998 Clinical Cancer Research 869 Expression of the Plasminogen Activation System in Kidney Cancer
- Nature Macmillan Publishers Ltd 1997 Epidemiological studies suggest that the
- Proc. Nati. Acad. Sci. USA Vol. 85, pp. 4128-4132, June 1988
- INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 8: 0-00, 2001 Binding site of amiloride to urokinase plasminogen
- electronic reprint Acta Crystallographica Section D
- INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 13: 759-766, 2004 Plasminogen activator inhibitor type 1 its structure,
